Research guide
CJC-1295 & Ipamorelin: a scientific overview
CJC-1295 and Ipamorelin are two synthetic peptides frequently paired in preclinical research on the growth-hormone (GH) axis. CJC-1295 is a GHRH analog; Ipamorelin is a selective growth-hormone-releasing peptide (GHRP).
For laboratory research use only. Not for human consumption, diagnostic or therapeutic use.
CJC-1295 (with or without DAC)
CJC-1295 is a 30-amino-acid analog of GHRH (1-29) with four substitutions that resist enzymatic degradation. The DAC (Drug Affinity Complex) variant carries a maleimide moiety that covalently binds serum albumin, extending its plasma half-life from minutes to days. The no-DAC form (also known as Mod-GRF 1-29) has a short half-life and is typically used for pulsatile stimulation studies.
Ipamorelin
Ipamorelin is a pentapeptide GHRP that binds the ghrelin/GHS-R1a receptor. Compared to earlier GHRPs such as GHRP-6 or hexarelin, it is highly selective — with negligible effect on cortisol, prolactin or ACTH in published preclinical models — which makes it a common tool compound for isolating GH-axis effects.
Why the combination?
GHRH analogs (CJC-1295) and GHRPs (Ipamorelin) act on distinct receptors and produce a synergistic GH pulse when co-administered in animal studies: CJC-1295 raises baseline somatotroph readiness while Ipamorelin triggers release. This combination is one of the most-cited pairings in preclinical GH-axis research.
Reconstitution & storage
Both peptides are supplied lyophilised and reconstituted with bacteriostatic water for injection. Reconstituted material should be stored at 2–8 °C, protected from light, and used within 30 days. Unreconstituted vials remain stable long-term at −20 °C.
Quality & purity
Every batch is characterised by reversed-phase HPLC and mass spectrometry, released at ≥ 99% purity and cross-verified by an independent European laboratory. A batch-specific certificate of analysis accompanies every order.
Frequently asked questions
CJC-1295 with DAC vs no-DAC — which to use?
The DAC form gives a sustained GH elevation and is used when constant exposure is desired. No-DAC preserves the natural pulsatile pattern of GH release and is closer to endogenous physiology in study designs.
Does Ipamorelin raise cortisol?
Published preclinical data (Raun et al., Eur. J. Endocrinol., 1998) reported minimal effect of Ipamorelin on cortisol, prolactin and ACTH at effective GH-releasing doses, distinguishing it from earlier GHRPs.
Are these peptides approved medicines?
No. Neither CJC-1295 nor Ipamorelin has EMA or FDA marketing authorisation. Both are supplied strictly for laboratory research.